Start here if you're new
what it is
The Joint runs chiropractic clinics and lets patients pay cash instead of using insurance.
how it gets paid
Last year The Joint made $52M in revenue. Franchise royalties and fees was the main engine at $27.5M, or about 53% of sales.
what just happened
Latest print on this page: on the order of ~$13M quarterly revenue against ~$52M annual, with EPS around $0.07 in the earnings block—check the 10-Q for the exact quarter.
At a glance
B balance sheet — gets the job done, barely
20/100 earnings predictability — expect surprises
trailing P/E is noisy while FY prints swing around breakeven—use filings, not a single screen multiple
3.4% return on capital — nothing to write home about
-$0.11 fy2024 eps est
xvary composite: 39/100 — weak
What they do
The Joint runs chiropractic clinics and lets patients pay cash instead of using insurance.
Private pay means patients pay cash, not insurers, so billing stays simple. That matters when you have 967 clinics across 41 states and the District of Columbia. Once you are in, your records live in Joint’s own system, and leaving gets annoying fast.
How they make money
$52M
annual revenue
Franchise royalties and fees
$27.5M
Company-owned clinic visits
$13.7M
Membership plans
$11.0M
Other revenue
$2.7M
The products that matter
royalty-based franchise income
Franchise Royalties & Fees
$27.5M · ~53% of sales
this is the cleanest revenue stream in the story. it produced $27.5M on the segment table above across 967 clinics—franchise economics matter more than raw door count alone.
core segment
company-owned clinic operations
Corporate Clinic Revenue
$13.7M · company-owned
company-owned clinic revenue prints at $13.7M here; refranchising can move this line down over time as economics shift toward royalties.
model reset
franchise support and fund admin
Advertising & Other
$11M memberships · $2.7M other
membership plans (~$11M) plus other revenue (~$2.7M) round out the ~$52M annual picture—small lines, but they show whether the network is still active while the model shifts.
support layer
Key numbers
~$13M
quarterly revenue (approx.)
Roughly one-fourth of the ~$52M annual total—use the 10-Q for the exact quarter; ignore the old $90M scrape.
-$0.11
FY2024 EPS (est.)
Negative FY print on the scoreboard above—multiples are not a clean valuation shortcut here.
1.65
beta
This stock moves harder than the market. That matters when the earnings story is still shaky.
967
clinic count
This is the scale behind the brand. It is also the reason every small operational change matters.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 10 / 100
- long-term debt $2M (2% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for JYNT right now.
source: institutional data · return history unavailable
What just happened
beat estimates
The Joint posted about ~$13M in quarterly revenue (order of magnitude) and $0.07 EPS—aligned to ~$52M annual revenue, not $90M.
Prior copy claimed $90M and 199% vs. prior year growth; that is inconsistent with the ~$52M annual revenue table on this page. Use EDGAR for the exact quarter and growth rate.
~$13M
qtr revenue (approx.)
$0.07
eps (Q)
78.7%
gross margin (Q)
revenue shock
The fix that mattered is scale: quarterly company revenue belongs next to tens of millions annually, not a $90M quarter on a ~$52M year.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is a franchise slowdown hiding inside a refranchising story: if mature clinics stop growing and new openings slip, the cleaner model will not matter because the network itself stops compounding.
high
same-clinic demand cools
This business sells repeat visits, not one-time hardware. If mature clinics lose traffic, system-wide sales weaken and the franchise case loses its easiest proof.
system-wide sales were $530.3M in 2024. that number needs to climb toward the $550M–$570M guide, not stall below it.
med
refranchising stays messy longer than expected
Corporate clinic revenue fell to $11.0M. That is fine if royalties replace it with cleaner economics. It is a problem if reported revenue shrinks faster than margins improve.
you can tolerate weaker headline revenue for a while. you cannot tolerate weak revenue and no margin payoff.
med
the multiple stops forgiving the mess
A 45.7x trailing p/e asks investors to trust the cleanup before the income statement fully shows it. That is generous for a stock with 20/100 earnings predictability.
if openings miss the 30–40 guide or earnings stay thin, valuation has room to compress even without a balance sheet crisis.
A weaker consumer wallet, slower openings, or flat network sales would hit the same thesis from three angles at once. That is why this stock can look optically cheap at $119M market cap and still disappoint.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next earnings update
You want one answer from the next print: did the franchise mix get cleaner because the business improved, or because reported revenue got smaller again.
trend
system-wide sales versus the $550M–$570M guide
That range is the cleanest scoreboard on the page. Hit it, and the network still has momentum. Miss it, and the turnaround loses air.
risk
mature clinic fatigue
A 960-clinic network sounds impressive until older locations stop pulling their weight. If mature clinics flatten out, the franchise pitch gets thin fast.
metric
new openings against the 30–40 target
Franchise interest is the live read on whether operators still want in. Fewer than 30 openings would tell you the story is losing traction where it matters.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak: the street does not have a clean consensus on how fast this cleanup can show up in earnings.
risk profile
volatile
price stability sits at 10 / 100. that is the score of a stock that can move hard on a small update.
business momentum
transitioning
the business is changing shape, which means clean trend lines are scarce. you are tracking execution milestones, not a steady compounder.
earnings predictability
20/100
earnings can swing because the mix between franchise revenue and corporate clinic revenue is still moving.
source: institutional data
Institutional activity
institutional ownership data for JYNT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$9
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive